RXFP2

Across TCGA pan-cancer cohorts, RXFP2 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated RXFP2 data layer compared with 5 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RXFP2 RNA is associated with better overall survival. In most high-consensus cancer types, elevated RXFP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LGG show a favorable association.

LUAD, READ, and LGG are the cancer types where RXFP2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.766	0.625	.004	42	view →
READ	DFS	Tertile	IV	0.182	0.668	.008	36	view →
LGG	OS	Tertile	All	0.931	0.825	<.001	32	view →
CESC	DFS	Tertile	II,III,IV	1.000	0.671	.026	18	view →
ESCA	OS	Median	III,IV	0.564	0.326	.026	13	view →
STAD	DFS	Quartile	IV	0.087	0.500	.003	12	view →
UVM	OS	Tertile	III,IV	0.241	0.765	.002	9	view →
SKCM	DFS	Tertile	IV	0.061	0.513	.033	9	view →
BRCA	OS	Tertile	All	0.902	0.931	.033	6	view →
LIHC	OS	Tertile	All	0.222	0.520	.039	6	view →
OV	DFS	Tertile	IV	0.650	0.423	.049	6	view →
KICH	DFS	Quartile	II,III,IV	0.523	0.894	.017	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

RXFP2–LUAD (OS)

Open the LUAD breakdown →